Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02269 WUXI BIO
RTNominal up13.480 +0.740 (+5.808%)
Others

01/11/2017 17:07

[I-bank focus]CS lowers Wuxi Biologics (02269) to "neutral"

[ET Net News Agency, 1 November 2017] Credit Suisse assumed coverage on Wuxi Biologics
(02269) with a "neutral" rating from "outperform" previously, and a target price of
HK$45.8.
The research house likes the company's expanding capacities for growing business volume
and its unique "follow the molecule" strategy. The company will take advantage of the
fast-growing biologic outsourcing industry with its c.50% market share in the China
market.
Credit Suisse believes that Wuxi will take more mAb discovery projects with its expanded
capacity and mAb business will be the next growth driver in the next five years. (KL)

Back to Others

Remark: Real time quote last updated: 26/04/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.